Brief: Zymeworks Q2 Operating Expenses USD 49.4 Million

Zymeworks

07/08/2025 21:05

Overview

Zymeworks Q2 2025 revenue rises to $48.7 mln, driven by milestone payments

Net income for Q2 2025 reaches $2.3 mln, reversing last year's loss

FDA clears IND for ZW251, first-in-human studies planned for 2025

Outlook

Company expects cash resources to fund operations into 2H-2027

Result Drivers

MILESTONE PAYMENTS - $20 mln milestone from BeOne for zanidatamab approval in China and $7.5 mln from BMS commercial license option

PARTNERSHIP REVENUE - Revenue driven by strategic partnerships and collaborations, including Jazz and J&J

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Net Income
$2.32 mln
Q2 Income From Operations
-$674,000
Q2 Operating Expenses
$49.40 mln
Q2 Pretax Profit
$2.13 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Zymeworks Inc is $19.50, about 36.4% above its August 6 closing price of $12.41

Press Release: ID:nGNXtVNdB

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)